THE PHENOMENON OF NEUTROPENIA DURING TOCILIZUMAB THERAPY IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS

THE PHENOMENON OF NEUTROPENIA DURING TOCILIZUMAB THERAPY IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS

Tocilizumab (TCZ) is one of the biological agents that are most commonly used in the treatment of juvenile idiopathic arthritis (JIA), especially its systemic variant. The development of neutropenia, which is associated with the use of TCZ and its mechanism of action, requires a detailed study. Base...

Full description

Bibliographic Details
Main Authors:	M. I. Kaleda, I. P. Nikishina, A. N. Shapovalenko, O. M. Kostareva, E. S. Fedorov
Format:	Article
Language:	Russian
Published:	IMA PRESS LLC 2018-01-01
Series:	Научно-практическая ревматология
Subjects:	tocilizumab neutropenia juvenile idiopathic arthritis biological drugs
Online Access:	https://rsp.mediar-press.net/rsp/article/view/2472

Similar Items

Optimization of systemic juvenile arthritis treatment regimens with correction of tocilizumab intravenous administration according to data of observational retrospective study
by: M. I. Kaleda, et al.
Published: (2019-05-01)

THE CLINICAL AND PARACLINICAL EFFICACY OF TOCILIZUMAB IN JUVENILE IDIOPATHIC ARTHRITIS
by: Ninel REVENCO, et al.
Published: (2021-06-01)

EFFICACY AND SAFETY OF TOCILIZUMAB IN CHILDREN WITH SYSTEMIC JUVENILE ARTHRITIS IN CLINICAL PRACTICE
by: M. I. Kaleda, et al.
Published: (2015-04-01)

Case reports Juvenile idiopathic arthritis complicated by amyloidosis with secondary nephrotic syndrome – effective treatment with tocilizumab
by: Małgorzata Kwiatkowska, et al.
Published: (2015-08-01)

Tocilizumab in Juvenile Idiopathic Arthritis Associated Uveitis, a Narrative Review
by: Claudia Iannone, et al.
Published: (2023-02-01)

Sequential Tocilizumab and Tofacitinib Treatment for Systemic Juvenile Idiopathic Arthritis: a Case Report
by: Ye Zhang, et al.
Published: (2022-11-01)

Tocilizumab in the treatment of systemic-onset juvenile idiopathic arthritis – single-centre experience
by: Justyna Roszkiewicz, et al.
Published: (2018-10-01)

Tocilizumab for juvenile idiopathic arthritis: a single-center case series
by: Fatma Yazılıtaş, et al.
Published: (2020-03-01)

A CASE REPORT OF THE USE TOCILIZUMAB IN REFRACTORY SYSTEMIC JUVENILE ARTHRITIS WITH PULMONARY INVOLVEMENT AND MACROPHAGE ACTIVATION SYNDROME
by: M. I. Kaleda, et al.
Published: (2015-09-01)

Tocilizumab in Systemic Juvenile Idiopathic Arthritis: Response Differs by Disease Duration at Medication Initiation and by Phenotype of Disease
by: Xin Yan, et al.
Published: (2021-11-01)

Tocilizumab may slow radiographic progression in patients with systemic or polyarticular-course juvenile idiopathic arthritis: post hoc radiographic analysis from two randomized controlled trials
by: Clara Malattia, et al.
Published: (2020-09-01)

Tocilizumab modifies clinical and laboratory features of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis
by: Masaki Shimizu, et al.
Published: (2020-01-01)

Risk of significant cytopenias after treatment with tocilizumab in systemic juvenile arthritis patients with a history of macrophage activation syndrome
by: Kessler Elizabeth A, et al.
Published: (2012-08-01)

Clinical improvement of renal amyloidosis in a patient with systemic-onset juvenile idiopathic arthritis who received tocilizumab treatment: a case report and literature review
by: Songkiat Chantarogh, et al.
Published: (2017-05-01)

Differences between leukemic arthritis and juvenile idiopathic arthritis
by: Alfonso Ragnar Torres Jimenez, et al.
Published: (2023-05-01)

Efficacy and safety of canakinumab as a second line biologic after tocilizumab treatment failure in children with systemic juvenile idiopathic arthritis: A single-centre cohort study using routinely collected health data
by: Ekaterina Alexeeva, et al.
Published: (2023-02-01)

Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry
by: Gerd Horneff, et al.
Published: (2017-11-01)

A CLINICAL CASE OF SYSTEMIC JUVENILE ARTHRITIS COMPLICATED BY RECURRENT MACROPHAGE ACTIVATION SYNDROME AND CHRONIC OSTEOMYELITIS OF THE CLAVICLE
by: M. I. Kaleda, et al.
Published: (2018-03-01)

Interstitial lung disease occurring shortly after tocilizumab infusion in a patient with polyarticular juvenile idiopathic arthritis: a case report
by: Koichi Sugihara, et al.
Published: (2021-09-01)

The necessity, efficacy and safety of biologics in juvenile idiopathic arthritis
by: Mustafa Cakan, et al.
Published: (2020-03-01)

Juvenile idiopathic arthritis – classification and methods of treatment
by: Weronika Pawłocik, et al.
Published: (2023-04-01)

Elbow monoarthritis: an atypical onset of juvenile idiopathic arthritis Elbow monoarthritis: an atypical juvenile idiopathic arthritis onset
by: G. Simonini, et al.
Published: (2012-07-01)

Uveitis in patients with oligoarticular juvenile idiopathic arthritis and juvenile spondyloarthritis/enthesitis related arthritis: is there any difference?
by: A. Martins, et al.
Published: (2023-05-01)

Juvenile idiopathic arthritis: from aetiopathogenesis to therapeutic approaches
by: Lina N. Zaripova, et al.
Published: (2021-08-01)

Juvenile Idiopathic Arthritis
by: Kenan Barut, et al.
Published: (2017-04-01)

Intravenous dosing of tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis: results from an open-label phase 1 clinical trial
by: Navita L. Mallalieu, et al.
Published: (2019-08-01)

First-line options for systemic juvenile idiopathic arthritis treatment: an observational study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans
by: Timothy Beukelman, et al.
Published: (2022-12-01)

Vitamin D and juvenile idiopathic arthritis
by: Sarah L. Finch, et al.
Published: (2018-05-01)

Risk of infection and disease activity of patients with juvenile idiopathic arthritis treated with and without biologics
by: S. Bouayad, et al.
Published: (2022-03-01)

Efficacy of rehabilitation therapy on hospital stage of treatment of patients with juvenile idiopathic arthritis
by: T A Shelepina, et al.
Published: (2008-06-01)

EXPERIENCE WITH ABATACEPT IN TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS
by: Margarita Fedorovna Dubko, et al.
Published: (2012-10-01)

IL-6 blockade in systemic juvenile idiopathic arthritis – achievement of inactive disease and remission (data from the German AID-registry)
by: M. Bielak, et al.
Published: (2018-04-01)

Interleukin 6 blockage-induced neutropenia in a patient with rheumatoid arthritis and resolved hepatitis B
by: Magdalena Chmielińska, et al.
Published: (2016-02-01)

Juvenile Idiopathic Arthritis and Exercise
by: Pınar Kısacık, et al.
Published: (2016-04-01)

Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis
by: İlknur Tuğal-Tutkun
Published: (2016-04-01)

Specific Features of Juvenile Idiopathic Arthritis Patients’ Cytokine Profile
by: Daria I. Kozlova, et al.
Published: (2024-01-01)

Drug survival and reasons for discontinuation of the first course of biological therapy in 301 juvenile idiopathic arthritis patients
by: M. Romano, et al.
Published: (2014-03-01)

Differences of hip involvement in systemic and non-systemic juvenile idiopathic arthritis
by: L. S. Sorokina, et al.
Published: (2022-03-01)

Current Treatments for Juvenile Idiopathic Arthritis
by: Alberto eMartini, et al.
Published: (2011-10-01)

Gene engineering biological therapy for juvenile arthritis
by: Kh Mikhel's, et al.
Published: (2011-02-01)